NCT06833645View on ClinicalTrials.gov

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

RecruitingOBSERVATIONAL
Enrollment

280

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

February 19, 2025

Study Completion Date

February 25, 2025

Conditions
Alzheimer's Disease
Interventions
OTHER

molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)

The new imaging agents Aβ and TauPET/CT are molecular imaging, which have the advantage of earlier and more visual, and can study the mechanism of pathological changes and PET manifestations of Alzheimer's disease before symptoms appear from the molecular level.

Trial Locations (1)

610072

RECRUITING

Departments of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Sichuan Provincial People's Hospital

OTHER